Patient Card

KEYTRUDA®
(pembrolizumab)

Important safety information to minimise the risk of immune-mediated adverse reactions

May cause some serious side effects which can sometimes become life-threatening and lead to death. These may happen any time during treatment or even after your treatment has ended. You may experience more than one side effect at the same time.

Contact your specialist right away if you develop any signs or symptoms, including those not listed on this card. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of pembrolizumab or stop treatment.

For more information, consult the relevant KEYTRUDA Patient Information Leaflet (PIL) for your location.
For Great Britain visit
https://www.medicines.org.uk/emc/
and for Northern Ireland visit
https://www.emcmedicines.com/en-gb/northernireland/
or call MSD Medical Information on Tel: 0208 1548000.

IMPORTANT

- Do not attempt to treat side effects yourself
- Do not stop your treatment with pembrolizumab unless you have discussed this with your doctor
- **Take this card with you at all times,** especially when you travel, whenever you go to the Accident and Emergency department, or when you must see another doctor
- Carry this card for at least 4 months after the last dose of pembrolizumab
- Be sure to notify any health care professional you see that you are being treated with pembrolizumab and show them this card
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD on Tel: 0208 1548000. By reporting side effects you can help provide more information on the safety of this medicine

Lungs
- Shortness of breath
- Chest pain
- Coughing

Intestines
- Diarrhoea or more bowel movements than usual
- Stools that are black, tarry, sticky, or contain blood or mucus
- Severe stomach pain or tenderness
- Nausea or vomiting

Liver
- Nausea or vomiting
- Feeling less hungry
- Pain on the right side of stomach
- Yellowing of skin or whites of eyes
- Dark urine
- Bleeding or bruising more easily than normal

Kidneys
- Changes in the amount or colour of your urine

Hormone glands
- Rapid heartbeat
- Weight loss or gain
- Increased sweating
- Hair loss
- Feeling cold
- Constipation
- Deeper voice
- Muscle aches
- Dizziness or fainting
- Headaches that will not go away or unusual headache

Type 1 diabetes, including diabetic ketoacidosis
- Feeling more hungry or thirsty
- Needing to urinate more often
- Weight loss
- Feeling tired or feeling sick
- Stomach pain
- Fast and deep breathing
- Confusion
- Unusual sleepiness
- A sweet smell to your breath
- A sweet or metallic taste in your mouth
- A different odour to your urine or sweat

Important Contact Information

Name of Specialist

Phone

After-hours Phone

My Name

My Phone

Emergency Contact (Name)

Emergency Contact (Phone)

Important Information for Health Care Providers

This patient is being treated with KEYTRUDA® (pembrolizumab), which can cause immune-mediated adverse reactions that may appear any time during treatment or even after treatment. Assess patients for signs and symptoms of immune-mediated adverse reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-mediated adverse reactions.

For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, withhold pembrolizumab and administer corticosteroids. **Specific guidelines for managing immune-mediated adverse reactions are available in the Summary of Product Characteristics for pembrolizumab.**

Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-mediated adverse reactions.

For more information, consult the relevant KEYTRUDA Patient Information Leaflet (PIL) for your location. For Great Britain visit https://www.medicines.org.uk/emc/ and for Northern Ireland visit https://www.emcmedicines.com/en-gb/northernireland/ or call MSD Medical Information on Tel: 0208 1548000.

MSD

Registered in England No. 233687 Date of preparation: September 2023. ONCO-Patient card.v14.0